Carole DEAN

Dr. Carole DEAN

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2023 in Diagnostic and Interventional Imaging
Verified
Journal Article
Open access
MSMarc Sapoval
Marc Sapoval
CQCharles Querub
Charles Querub
HPHelena Pereira
Helena Pereira
OPOlivier Pellerin
Olivier Pellerin
TBTom Boeken
Tom Boeken
FRFrançois Rannou
François Rannou
The purpose of this study was to evaluate the safety and efficacy of transient genicular artery embolization (GAE) using an ethiodized oil-based emulsion for the treatment of knee osteoarthritis (KOA). This prospective, single-arm, open-label, multicenter, first-in-human cohort trial was registered on ClinicalTrials.gov (NCT04733092). The main inclusion criterion was diagnosis of KOA according to a visual analogue scale (VAS) pain score ≥ 40 mm (score range: 0-100 mm), despite conservative treatment for at least three months. Treatment efficacy was assessed using changes in VAS pain score, Mean Western Ontario & McMaster Universities osteoarthritis (WOMAC) function score (normalized to 100; score ranging from 0 to100) and outcome measures in rheumatoid arthritis clinical trials (OMERACT)-Osteoarthritis Research Society (OARSI) set of responder criteria. Twenty-two consecutive participants (13 women; mean age, 66 ± 9 [standard deviation (SD)]) were included and underwent GAE. Emulsion consisted in a mixture of ioversol and ethiodized oil (ratio 1:3, respectively) prepared extemporaneously. The rate of serious adverse events attributed to GAE within one month was 5% (1/22), corresponding to reversible worsening of renal function. Immediate technical success rate was 100%. Mean VAS pain score dropped from 74.4 ± 16.5 (SD) mm at baseline to 37.2 ± 26.7 (SD) mm at three months (P < 0.001). Mean WOMAC function score (normalized to 100: score ranging from 0 to 100) decreased from 57.3 ± 17.1 (SD) at baseline to 33.5 ± 25.9 (SD) at three months (P < 0.001). At three months, 16 out of 22 participants (73%) were considered responders according to the OMERACT-OARSI set of responder criteria, including high improvement in either pain or WOMAC function, or improvement in both pain and WOMAC function. GAE using an ethiodized oil-based emulsion is safe and improves pain and function in participants with KOA for at least three months.

24 December 2015 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
GAGregory Amouyal
Gregory Amouyal
NTNicolas Thiounn
Nicolas Thiounn
OPOlivier Pellerin
Olivier Pellerin
LYLin Yen-Ting
Lin Yen-Ting
CGCostantino Del Giudice
Costantino Del Giudice
MSMarc Sapoval
Marc Sapoval

26 June 2023 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
MSMarc Sapoval
Marc Sapoval
NTNicolas Thiounn
Nicolas Thiounn
ADAurélien Descazeaud
Aurélien Descazeaud
CDCarole DEAN
Carole DEAN
ARAlain Ruffion
Alain Ruffion
AVAlexandra Vappereau
Alexandra Vappereau
Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient's symptoms improvement after PAE and medical treatment. A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) defined by International Prostatic Symptom Score (IPSS) > 11 and quality of life (QoL) > 3, and BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day). Randomisation was stratified by centre, IPSS and prostate volume with a minimisation procedure. The primary outcome was the 9-month IPSS change. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome. ClinicalTrials.gov Identifier: NCT02869971. Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups, respectively. The 9-month change of IPSS was −10.0 (95% confidence interval [CI]: −11.8 to −8.3) and −5.7 (95% CI: −7.5 to −3.8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (−4.4 [95% CI: −6.9 to −1.9], p = 0.0008). The IIEF-15 score change was 8.2 (95% CI: 2.9–13.5) and −2.8 (95% CI: −8.4 to 2.8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 9 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group, respectively. In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms benefit than CT up to 24 months. French 10.13039/100009647 Ministry of Health and a complementary grant from 10.13039/100019484 Merit Medical .

5 November 2015 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
YLYen-Ting Lin
Yen-Ting Lin
GAGrégory Amouyal
Grégory Amouyal
NTNicolas Thiounn
Nicolas Thiounn
OPOlivier Pellerin
Olivier Pellerin
HPHéléna Pereira
Héléna Pereira
MSMarc Sapoval
Marc Sapoval

1 August 2021 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MSMarc Sapoval
Marc Sapoval
VVVincent Vidal
Vincent Vidal
CDCarole DEAN
Carole DEAN
CGCostantino Del Giudice
Costantino Del Giudice
FTFarouk Tradi
Farouk Tradi
RLRomaric Loffroy
Romaric Loffroy

1 December 2021 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
OPOlivier Pellerin
Olivier Pellerin
CDCarole DEAN
Carole DEAN
PRPhilippe Reb
Philippe Reb
CCCeline Chaix
Celine Chaix
FFFranck Floch
Franck Floch
MSMarc Sapoval
Marc Sapoval